Posted by Michael Wonder on 17 Nov 2016
NICE approves three quarters of CDF group 1 drugs for routine use
17 November 2016 - More than 75% of treatments in the Cancer Drugs Fund which have been looked at again by NICE have received positive recommendations for routine NHS use.
It means that drugs, which patients previously had to apply to the Cancer Drugs Fund (CDF) for, will now be available routinely on the NHS.
NICE is currently reappraising 11 drug indications in the first group of the CDF, and of the nine looked at so far, seven have been approved at draft or final guidance stage. None have yet been rejected in final guidance, with the remaining two currently in the process.
The seventh drug was approved in draft guidance published on Thursday 16 November.
